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Abstract 
The assembly of proteins into complexes is fundamental to nearly all biological 
signalling processes. Symmetry is a dominant feature of the structures of 
experimentally determined signalling complexes, observed in the vast majority of 
homomers and many heteromers. However, some asymmetric structures exist, and 
asymmetry also often forms transiently, intractable to traditional structure 
determination methods. Here, we explore the role of protein complex symmetry and 
asymmetry in cellular signalling, focusing on receptors, transcription factors and 
transmembrane channels, amongst other signalling assemblies. We highlight a 
recurrent tendency for asymmetry to be crucial for signalling function, often being 
associated with activated states. We conclude with discussion of how consideration 
of protein complex symmetry and asymmetry has significant potential implications 
and applications for pharmacology and human disease.  
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Introduction 
Many if not most proteins can assemble into complexes in order to carry out their 
biological functions. The three-dimensional structures of tens of thousands of protein 
complexes have been experimentally determined to date, and have revealed a 
tremendous diversity of possible quaternary structure, i.e. the way the different 
subunits of a complex are arranged with respect to each other [1]. However, while 
the importance of protein interactions is widely recognised, the implications of higher-
order quaternary structure are often not considered when attempting to understand 
protein function and malfunction. 
Protein complexes can be divided into homomers, formed from multiple copies 
of the same protein, and heteromers, containing multiple distinct proteins. Recently, 
it has been shown that much of the diversity of protein quaternary structure observed 
in nature can be explained by a simple model based upon the possible transitions 
through which protein complexes can evolve, and which allows most known 
structures to be arranged into a “periodic table of protein complexes” [2]. Symmetry 
is a defining feature of this periodic table, as it allows the grouping of heteromeric 
complexes with topologically equivalent homomers from the same symmetry group. 
Approximately 96% of homomer structures can be classified into a limited set of 
closed symmetry groups [3,4]. For heteromers, if we exclude the 65% of structures 
that have no repeated subunits (e.g. heterodimers), then 79% are symmetric. Of 
those homomer or heteromer structures that are asymmetric, the majority are the 
result of quaternary structure assignment errors [2,5], or appear symmetric under 
equilibrium conditions in solution [6]. 
Despite the prevalence of symmetry in protein complex structures, biological 
asymmetry is common. In fact, since the early days of protein crystallography, with 
the observation that many proteins form symmetric complexes, the role of asymmetry 
has been discussed. While the Monod-Wyman-Changeux (MWC) model of allostery 
relies on the preservation of global symmetry [7], the subsequent Koshland-
Némethy-Filmer (KNF) model is dependent upon the simultaneous adoption of 
distinct conformations by different subunits within the same complex [8]. The 
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asymmetry allowed by the KNF model can explain the negative cooperativity 
observed in some proteins, which is not accounted for by the MWC model [9]. 
Asymmetry in protein complexes can generally occur in two different ways. 
First, there are protein complexes that have their structures determined in a 
genuinely asymmetric state. If we exclude heteromers with no repeated subunits (i.e. 
1:1 stoichiometry), then   For instance, complexes with uneven (odd) stoichiometry 
(which comprise ~25% of heteromeric structures with repeated subunits) necessarily 
contain some degree of asymmetry as sequence-identical subunits must form 
different interactions within the complex [2,10]. Second, asymmetry is often transient 
and unobservable to traditional structure determination methods, but detectable 
using various biochemical and biophysical techniques. Interestingly, asymmetric 
states of protein complexes are often conducive to the biological functions of 
signalling complexes, as we will discuss in this review. 
A variety of different biophysical methods are available to address symmetry-
related issues, and their strengths and limitations have been recently compared [11]. 
X-ray crystallography has remained a major method to reveal atomic differences 
between subunits of complexes and thus asymmetry, but is limited by the difficulty of 
crystallising many proteins, and the fact that it presents only a static snapshot of 
protein structure. Due to methodical advances, single particle cryo-electron 
microscopy has recently reached near-atomic resolution and is quickly becoming a 
major method to elucidate distinct (a)symmetric states of large complexes [12]. The 
shape, assembly state of these large complexes in solution can be confirmed with 
small-angle X-ray or neutron scattering. Mass spectrometric methods have 
increasingly become more efficient and complementary to determine the molecular 
weight and thus the stoichiometry of large assemblies in solution [13]. 
One important caveat to consider when analysing X-ray or electron 
microscopy structures is that symmetry constraints are often utilised, which 
essentially assume that symmetry is present and that different copies of the same 
subunit are in identical conformations [14]. While such symmetry constraints are 
currently necessary to obtain a structure solution in many cases, particularly for large 
structures where the resolution is poor, they have the potential to mask small or 
localised asymmetry. 
4 
The detection of the shortest-lived events needs site-specific labelling with 
paramagnetic atoms, fluorescent or luminescent markers based on stereo-structural 
knowledge. Single molecule fluorescence and bioluminescence resonance energy 
transfer measurements have outstanding potential to reveal the temporal and 
structural details of activation. Nuclear magnetic and electron paramagnetic 
resonance spectroscopies in solid state and solution, respectively, can be used to 
probe local conformation and rapid structural changes. Finally, molecular dynamics 
simulations can mimic asymmetric transition states approaching the μs timescale. 
Complementary combinations of these methods with biochemical and 
nanotechnological ones can elucidate the asymmetric activation of signalling 
complexes more and more reliably [15]. 
In this review, we discuss the role of protein complex symmetry and 
asymmetry in protein complexes involved in signalling processes. In particular, we 
focus on GPCRs, other dimeric receptors and transcription factors, and 
transmembrane channels and transporters, showing that, while many of these 
complexes have symmetric structures, asymmetry is often important for their function 
and regulation. An overview of some of the main examples discussed in this review 
is provided in Table 1. We also consider the implications of protein complex 
(a)symmetry for pharmacology and in understanding the molecular mechanisms of 
human disease. Finally, through a simple analysis of known protein quaternary 
structures, we highlight an overrepresentation of both symmetric and asymmetric 
complexes amongst proteins known to be drug targets or associated with genetic 
disease or cancer.  
Multiple levels of symmetry and asymmetry in G protein-coupled receptors 
G protein-coupled receptors (GPCRs) are the largest group of drug targets and serve 
as a challenge for the development of allosteric modulators and GPCR subtype-
selective drugs exploiting the heterogeneity of signalling [16–19]. Recent advances 
in X-ray crystallography have led to successful determination of several structures of 
GPCR transmembrane regions. While most structures are monomeric, proteins in 
three different GPCR classes have been crystallised as symmetric homodimers [20–
22]. However, despite this symmetry, there is considerable evidence that transient 
asymmetry can occur between the dimeric subunits upon interaction with other 
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proteins or small molecules. For example, oligomeric states of various GPCRs have 
been detected in native tissues using fluorescence resonance energy transfer [23], 
and there appears to be asymmetry between the dimer subunits in a short-lived 
intermediate state [24]. Other studies have highlighted asymmetry in the ligand-
activated states of metabotropic glutamate receptors (mGluRs) [25], agonist-bound 
leukotriene B4 receptors [26], serotonin 5-HT2c receptors [27] and dopamine D1-D2 
receptors [28,29]. Some GPCRs, such as dopamine D2 and GABAB receptors, can 
form pseudosymmetric heterodimers, and this pseudosymmetry can be broken upon 
transactivation [30–33]. 
Only a single structure of a GPCR in complex with a heterotrimeric G protein 
has been published [34]. Although it involves a monomeric GPCR (β2 adrenergic 
receptor) and so has even (1:1:1:1) stoichiometry (Figure 1A), a homodimeric GPCR 
can also activate G proteins with asymmetric uneven stoichiometry [35–37]. For 
example, one regulator of G-protein signalling and one Gi can bind asymmetrically to 
separate protomers of a melatonin receptor dimer that rearranges upon agonist 
activation [38]. Similarly, a single C-terminal domain of GPCR and (rhod)opsin 
dimers binds intracellular regulatory proteins such as arrestin [39–41]. Finally, a 
recent analysis of the proteome of native GABAB receptor signalling has revealed 
uneven stoichiometries where the core assemblies contain GABAB1a/b, GABAB2, four 
channel tetramerisation domains and distinct G protein subunits [42]. 
Higher-order structures are also possible for GPCRs [37]. For example, the 
extracellular domain of follicle-stimulating hormone (FSH) receptor assembles into a 
symmetric homotrimer, and can form an even (3:3:3) stoichiometry complex with 
FSH α and ß [43]. Upon interaction with a heterotrimeric G protein, an asymmetric 
uneven stoichiometry complex may be formed [44]. Although no structure is available 
for this full complex, we can combine available structures with our knowledge of the 
stoichiometry to build a speculative model of this 3:3:3:1:1:1 complex (Figure 1A). 
There is also evidence that GPCRs can exist as homotetramers and heterotetramers 
[45,46], which can allosterically influence the potencies and efficacies of agonists 
[18,19,47]. Examination of crystal packing in dimers provided possible structures of 
GPCR tetramers [35,48,49]. Due to the non-equivalent positions of subunits, these 
tetramers are asymmetric, or “non-bijective” according to the nomenclature of the 
periodic table of protein complexes [2]. Although a majority of non-bijective homomer 
6 
structures are the result of quaternary structure assignment errors [2], they can 
nevertheless be used to putatively model how a GPCR tetramer can simultaneously 
bind two different heterotrimeric G proteins with uneven (4:2:2:2) stoichiometry [35] 
(Figure 1A). Finally, rhodopsin dimers have been observed to form higher-order 
assemblies in native disc membranes [50]. 
Dimeric receptors and transcription factors: activation and breaking of twofold 
symmetry 
In addition to GPCRs, there are many other signalling proteins that form 
homodimers, e.g. transmembrane receptors like receptor tyrosine kinases, and 
transcription factors, including nuclear receptors. While most of the known structures 
of these proteins have twofold symmetry, asymmetry is often important for their 
activation and function, in particular due to the uneven stoichiometry of their 
interactions with ligands or other proteins. Any interaction with uneven stoichiometry 
will necessarily be asymmetric, unless the ligand itself is symmetric [10]. For 
example, asymmetric 2:1 complexes have been observed for a variety of receptor-
ligand complexes, as we illustrate for interleukin 17A [51] and prolactin [52] in 
complex with their receptors (Figure 1B). In these structures, since the ligand binds 
at or near the dimer interface, the two receptor subunits will necessarily interact in 
different ways. Other receptor-ligand complexes with evidence for 2:1 stoichiometry 
when activated include bone morphogenic protein [53], insulin [54], fibroblast growth 
factor [55] and mammalian target of rapamycin (mTOR) kinase [56]. 
For dimeric transcription factors, symmetry is often broken in a similar way, 
due to the interaction of a symmetric dimer with asymmetric double-stranded DNA. 
Thus, asymmetry is often observed in the DNA-bound state of transcription factors. 
For example, the homodimeric retinoid X receptors bind co-operatively but 
asymmetrically to DNA repeats [57] (Figure 1B). Similarly, diabetes-related 
hepatocyte nuclear transcription factors homodimerise and form an asymmetric 
complex with the DNA response element [58] (Figure 1B). The heat-shock factor 
HSF1 presents a particularly interesting case: upon stress, it can trimerise via its 
coiled-coil domain and wraps around its DNA in an asymmetric manner [59]. In 
contrast, some transcription factors bind at palindromic sequences or inverted 
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repeats [60], which have local twofold symmetry, and thus symmetry can be 
preserved in the DNA-bound state [61]. 
Asymmetry can be also observed at the level of the dimer alone, such as the 
cytoplasmic kinase domain of epidermal growth factor receptor (EGFR), which was 
crystallised as a symmetric dimer in its autoinhibited state, but as an asymmetric 
dimer in its activated form [62] (Figure 1B), showing that asymmetric dimer 
rearrangement is essential for kinase activation. Similarly, the cytoplasmic region of 
the bacterial receptor histidine kinase CpxA crystallised as an asymmetric dimer, 
suggesting that chemotaxis signalling is a highly dynamic process that occurs via 
asymmetric rearrangement of the catalytic domains [63]. Although there are no 
mammalian orthologues, the bacterial histidine kinases are emerging as potential 
antibiotic drug targets [64]. 
The aberrant (a)symmetry of dimeric signalling complexes is often intimately 
associated with pathogenesis, particularly cancer. For example, disease-related 
mutations in the dimer interfaces of kinase domains can potentially impair the 
activation of various growth factor receptors and kinases [65]. Mig6 and anticancer 
drugs inhibit EGFR and drive internalisation via uneven (2:1) stoichiometry 
complexes, while oncogenic mutants may form even (2:2) stoichiometry complexes 
with Mig6 [66]. Tyrosine kinase inhibitors can enhance symmetric or 
pseudosymmetric EGFR interactions, thus restructuring the network of EGFR 
interactions [67]. An oncogenic missense mutation of the fibroblast growth factor 
receptor FGFR4 gene exposes a binding site for STAT3, a signal transducer and 
activator of transcription, which alters the stoichiometry and enhances STAT3 
signalling [68]. Haem-dependent symmetric dimerisation of sigma-2 receptors 
facilitates cancer proliferation and chemoresistance [69]. 
Transient and permanent asymmetry in oligomeric transmembrane channels 
and transporters 
Ligand- and voltage-gated ion channels are activated by chemical and physical 
signals. Although these transmembrane channels typically have cyclic symmetry or 
pseudosymmetry [70,71], asymmetry often occurs through their interactions with 
other proteins. For example, skeletal muscle ryanodine receptors are 4-fold 
8 
symmetric homotetramers [72] (Figure 1C) that can interact asymmetrically via their 
C-terminal intracellular domains with other integral membrane proteins, such as the 
9-fold symmetric caveolin-3 [73]. Similarly, cardiovascular KATP and voltage-activated 
(Shaker) Kv potassium channels are 4-fold symmetric [74], and their clustering 
requires binding of the C-terminal disordered domains to PSD-95 scaffold proteins, 
presumably with uneven stoichiometry [75]. Finally, purinergic P2X7 receptor trimers 
form uneven stoichiometry complexes with symmetric pannexin-1 channels involved 
in cardioprotection [76]. 
Some transmembrane channels are pseudosymmetric heteromers with 
paralogous subunits, presumably having evolved from symmetric homomers via 
gene duplication [77]. If the ancestral homomer has an even number of subunits, 
then even stoichiometry can be maintained after gene duplication. However, gene 
duplication will cause a cyclic ring with an odd number of subunits to evolve with 
uneven stoichiometry. For example, members of the Cys-loop superfamily of 
neurotransmitter receptors are pentameric ligand-gated ion channels (pLGIC) fine-
tuned by allosterically modulating drugs [78]. Bacterial pLGICs are symmetric 
homopentamers [79,80], while most mammalian pLGICs are pseudosymmetric 
heteropentamers with uneven stoichiometry [81,82]. Distinct auxiliary subunits confer 
tissue selectivity, such as in muscle-type pseudosymmetric α2ßγδ nicotinic 
acetylcholine receptors [76] (Figure 1C). Activation of Cys-loop receptors requires 
agonist binding in three cavities of non-consecutive subunit interfaces [83,84], thus 
breaking pseudosymmetry [78,85]. In contrast, ligand occupation of all five binding 
clefts restores pseudosymmetry, resulting in desensitisation and channel closure 
[85]. Interestingly, rescue of truncated pLGIC function by domain complementation 
needs inter-familial co-assembly and thus uneven stoichiometry [86]. 
The homotetrameric crystal structure of the antagonist-bound AMPA-type 
GluA2 ionotropic glutamate receptor (iGluR) revealed an interesting case of mixed 
symmetries: the transmembrane region has 4-fold cyclic symmetry, while the 
extracellular domains form a pair of symmetric dimers [87]. The agonist-bound active 
form showed conformational changes leading to deeper expansion of the twofold 
symmetry of the extracellular domains and increased tension in the linkers 
connecting ligand-binding domain to the N-terminal and transmembrane domains 
[88]. When activated by a homodimeric cone snail toxin, GluA2 forms an uneven 
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(4:2) stoichiometry complex where asymmetric constraints by the toxin across the 
ligand-binding domain force the opening of the channel [89] (Figure 1C). AMPA-type 
iGluR homotetramers co-assemble with a regulatory protein stargazin, mostly with 
uneven (4:3) stoichiometry [90]. When these complexes bound antagonists, they 
showed twofold symmetry [91]. Finally, all types of iGluRs (AMPA, kainite and 
NMDA) can form paralogous heterotetramers with global twofold symmetry, as well 
as twofold pseudosymmetry in the extracellular domains and 4-fold pseudosymmetry 
in the transmembrane region [92–94] (Figure 1C). 
While signal-activated transmembrane channels enable the flux of chemicals 
down their concentration gradients, active transporters are needed to expel 
undesired substances or accumulate necessary ones. Many membrane transporters 
are also symmetric oligomers [71]. Some transporters undergo rapid symmetry-
violating transitions between outward- and inward-facing conformations, around 
twofold and 3-fold pseudosymmetric assemblies with even stoichiometries and/or 
intramolecular inverted repeats [95]. However, auxiliary subunits result in further 
asymmetry. The ATP-driven TrkH belongs to the superfamily of K+ transporters. TrkH 
dimers and ATP-bound TrkA tetramers form symmetry-breaking uneven 
stoichiometry assemblies [96]. At the active mitochondrial protein gate the 
preprotein-translocating trimeric complex of rings reassembles into dimeric 
translocator of the outer membrane (TOM) rings [97]. 
Many pathogenic mutations have been associated with symmetric 
transmembrane channels and these “channelopathies” are challenging targets for 
selective drugs [98–100]. Interestingly, the mutations are often autosomal dominant, 
and thus asymmetric at the gene level (i.e. heterozygous). Thus, these mutations 
can break the symmetry of complexes, as they will assemble with a mixture of wild 
type and mutated subunits. This phenomenon allows for a dominant-negative 
mechanism, assuming that all complexes containing at least one mutated subunit 
experience a loss of function [101], and assembly does not occur co-translationally 
[102,103]. In the example shown in Figure 2, 1/16 of the assembled complexes will 
be C4 symmetric wild-type homomers, 1/16 will be C4 symmetric mutant homomers, 
2/16 will be C2 symmetric heteromers and 10/16 will be asymmetric heteromers. 
Interestingly, however, dominant-negative mutations in transmembrane channels 
tend to be less structurally destabilizing than recessive or other dominant mutations, 
10 
as the dominant-negative mechanism requires that the complex is still able to 
assemble [104]. 
Pharmacological implications of symmetry and asymmetry 
We have discussed a number of pharmacologically relevant complexes with 
evidence for transient or permanent asymmetry. However, beyond simply knowing 
that many signalling complexes are often symmetric or asymmetric, how can 
knowledge and understanding of the principles of protein complex symmetry and 
asymmetry help pharmacology? 
 Perhaps most importantly, there appears to be a regular tendency for 
symmetry to be associated with inactive states and asymmetry to be associated with 
activation. This has important pharmacological implications. Pharmacological 
blockade by antagonists requires stabilisation of an inactive state, which could 
involve interface binding to strengthen symmetric homomeric interactions, or to 
prevent asymmetric, usually heteromeric interactions. Symmetry considerations can 
even be extended to the small-molecule level: symmetric organic anions and 
calixarenes can match the symmetry and inhibit homomeric pLGICs [105] and 
voltage-dependent Kv channels [106] 
In contrast, agonist-elicited signal transductions either weaken initial interface 
interactions or foster subsequent subunit attachments which can result in asymmetric 
reassembly. This is illustrated by product-elicited complex reassembly of arginine 
methyltransferase with its coactivator CARM [107]. In addition, a bacterial 
homopentameric pLGIC model of mammalian GABAA receptors revealed that 
potentiation by sedative benzodiazepine drugs needs asymmetric interface binding 
of agonists and allosteric agents for channel opening [108]. Glycine and GABAA 
receptor concatemers with constrained stoichiometry also demonstrated asymmetric 
contributions of subunits to activation [109], and potentiation by anaesthetic alcohols 
(e.g. propofol) needs asymmetric binding patterns in transmembrane cavities [79,85]. 
Some viral antigenic peptides are transported into the endoplasmic reticulum 
by a transporter associated with antigen processing (TAP) and then onto the major 
histocompatibility complex. An inhibitory protein of herpes simplex virus can 
asymmetrically bind and stabilise the pseudosymmetric TAP dimer in a cytosol-facing 
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state, which is a valuable tool for selective immunosuppression [110]. Any inhibitor 
working via a similar mechanism to “plug” a (pseudo)symmetric transporter or 
channel would necessarily require a similar asymmetric mode of binding, or else be 
symmetric itself to match the symmetry of complex. 
Antibody design can be aided by symmetry considerations. For example, 
antigen binding induces the symmetric hexamerisation of IgG, which allows the 
formation of activating complexes with C1, the first component of complement 
[111,112]. In addition, recent reports describe the structures of neutralizing 
antibodies forming 3-fold symmetric complexes with the envelope glycoprotein 
trimers of HIV and Ebola viruses [113–115].  
Finally, it is important to consider the fact that asymmetry can sometimes lead 
to counterintuitive pharmacological effects. For example, identical subunits within the 
same complex can behave in different ways, as seen in asymmetric GPCR dimers 
where agonists can bind to different subunits with different affinities and efficacies 
[18,116]. 
Analysis of quaternary structure supports the pharmacological and biomedical 
importance of symmetry and asymmetry 
Another way to illustrate the biomedical and pharmacological importance of 
quaternary structure is with a structural bioinformatic approach. The huge number of 
protein structures now available allows to classify human protein-coding genes on 
the basis of their quaternary structure: whether they are known to form a symmetric 
or asymmetric homomer or heteromer, or whether they are monomeric with no 
evidence of complex formation. We used these classifications to investigate how 
frequently different types of protein quaternary structures are associated with human 
protein-coding genes that are known to be drug targets [117], associated with a 
Mendelian genetic disease [118], or associated with cancer [119] (Figure 3). 
Importantly, we emphasise that the fact that proteins are drug targets or associated 
with genetic disease or cancer are not independent of each other - this allows us to 
highlight the potential role of symmetry and asymmetry in biomedically relevant 
proteins. 
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 Overall, the most striking observation is that human proteins that assemble 
into complexes are significantly more likely to be drug targets or be associated with 
genetic disease or cancer than monomeric proteins. The difference between 
symmetric and asymmetric structures is small, but this is confounded by the fact that 
asymmetric structures are often the result of quaternary structure assignment errors 
[2], and that symmetric complexes can adopt transient asymmetry. However, 
symmetric structures do appear to have a slightly stronger tendency to be drug 
targets or be associated with genetic disease. For example, symmetric heteromers 
are significantly more likely to be drug targets than asymmetric heteromers (P = 
0.006, Fisher’s exact test). 
For the most part, there is little apparent difference between homomers and 
heteromers - both are similarly enriched as drug targets and in genetic disease 
compared to monomers. The exception is the cancer-associated genes, where the 
subunits of heteromers are highly enriched compared to homomers (P = 2 x 10-7, 
when heteromeric and homomeric subunits are grouped). This may reflect the 
tendency for cancer genes to be involved in signalling pathways requiring 
interactions between distinct proteins [120]. 
There are a number of potential caveats related to this simple approach. In 
particular, quaternary structure can be dynamic, e.g. a single protein may exist as a 
monomer or as a part of different homomers and heteromers. Furthermore, different 
quaternary structures may be associated with different biological functions [121], e.g. 
transmembrane channels often have cyclic symmetry [71], and allosteric enzymes 
are often dihedral [3]. Since transmembrane channels are often drug targets and 
metabolic enzymes are often associated with Mendelian genetic disorders, the 
associations we see may reflect the fact that different forms of oligomerisation can 
facilitate different biological functions. Finally, the low association of proteins without 
published structures with all three groups is probably due to the fact that proteins of 
biomedical interest are more likely to have been studied experimentally. 
Nevertheless, this analysis supports the general importance of proteins that 
assemble into symmetric and asymmetric complexes, as they are more likely to be 
drug targets or associated with disease. 
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Conclusions and perspectives 
Major advances have been made in recent years in our ability to experimentally 
characterise symmetric and asymmetric quaternary structure. Although X-ray 
crystallography has revealed symmetric structures for thousands of protein 
complexes, this has led to a somewhat artificial sense of the dominance of 
symmetry. As we have shown here, asymmetry is probably more common than the 
static crystallographic picture reveals, and the importance of asymmetry to dynamic 
cellular processes is becoming increasingly clear. In particular, we see a frequent 
correlation between symmetry breaking and biological function or activation. 
However, since these asymmetric, active states are often higher energy and 
transient, they are more difficult to detect experimentally. Instead, we must often rely 
on indirect methods to observe or infer the presence of asymmetry. Future 
improvements in these techniques, integrated with detailed molecular simulations 
and improved knowledge of the principles that underlie symmetric and asymmetric 
quaternary structure organisation [2,10], will allow us to understand the full spectrum 
of symmetric and asymmetric states associated with various signalling processes 
occurring within cells, including the emerging concept of hierarchical, dynamic 
signalling assemblies called signalosomes [122]. 
Symmetry is a unifying concept in a broader sense [123]. It has remained 
largely unaddressed in pharmacological studies and constrained in structural biology. 
We still lack a complete picture of the role of asymmetry in cellular signalling, and we 
cannot answer the majority of basic questions unambiguously yet. Better 
consideration of symmetry and asymmetry will improve both our understanding of 
cellular signalling processes at a molecular level, and our ability to target them 
pharmacologically. 
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Figure 1: Symmetry and asymmetry in the structures of signalling complexes. 
(A) Structure of a GPCR in complex with a heterotrimeric G protein, having even 
(1:1:1:1) stoichiometry (PDB ID: 3SN6), and putative models of complexes of other 
GPCRs forming uneven stoichiometry complexes (2:1:1:1, modelled from 4GPO; 
4:2:2:2, modelled from 4DKL; and 3:3:3:1:1:1, modelled from 4AY9 for the 
extracellular domain, while the transmembrane region was modelled with SWISS-
MODEL [124] and M-ZDOCK [125]. (B) Asymmetric structures of dimeric receptors 
(PDB IDs: 4HSA, 3NPZ, 4CN2, 4IQR and 2GS6). (C) Symmetric and 
pseudosymmetric structures of transmembrane channels (PDB IDs: 4UWE, 4PE5, 
4U5B and 4BOI). 
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Figure 2: The dominant-negative effect in symmetric homomers. 
Illustration of the dominant-negative effect using the structure of homotetrameric 
InsP3R1 (PDB ID: 3JAV) [126], which is mutated in Gillespie syndrome and 
spinocerebellar ataxia [104,127]. In the case of heterozygous disease mutations and 
random association of proteins, 15/16 tetramers will contain at least one mutated 
subunit. 
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Figure 3: Structural bioinformatic analysis of the biomedical and 
pharmacological importance of protein complex symmetry and asymmetry. 
Human protein-coding genes were classified based upon the type of protein structure 
formed in the Protein Data Bank. Drug target genes were taken from the Guide to 
Pharmacology [117]. Genes with a Mendelian genetic disease association were 
taken from OMIM [118]. Genes with a known cancer association were taken from 
COSMIC [119]. For human genes mapping (>70% sequence identity) to multiple 
structures, on a single quaternary structure classification was assigned: the highest 
category from top to bottom in the above plot (e.g. a gene mapping to a symmetric 
homomer and a monomer was classified as a symmetric homomer). P-values were 
calculated using Fisher’s exact test comparing subunits from different types of 
complexes to monomers, indicated by * (P ≤ 0.01), ** (P ≤ 0.0002) and *** (P ≤ 3 x 
10-6).  Error bars represent 68% Wilson binomial confidence intervals. 
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Table 1: Key examples of symmetry breaking in signalling complexes 
Example Description 
GPCRs Dimer symmetry can be broken through formation 
of uneven stoichiometry complexes with regulatory 
proteins or small molecules, or upon formation of 
higher-order oligomers. 
Nuclear receptors Many nuclear receptors are symmetric dimers, but 
this symmetry can be broken upon interaction with 
asymmetric double-stranded DNA. 
EGFR Forms a symmetric dimer in its autoinhibited state, 
but rearranges to an asymmetric dimer upon 
activation. 
pLGICs Mammalian heteropentamers formed from 
paralogous subunits are pseudosymmetric with 
uneven stoichiometry, while pseudosymmetry is 
broken upon activation by asymmetric ligand 
binding. 
iGluRs Homotetramer shows a mixture of C2 and C4 
symmetry, which is broken upon accessory protein 
or toxin binding with uneven stoichiometry. 
 
